Advertisement

Reactions Weekly

, Volume 1733, Issue 1, pp 24–24 | Cite as

Alemtuzumab

Systemic sarcoidosis: 3 case reports
Case report
  • 14 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective case series of 187 patients from two UK specialist centres, three patients (2 women and 1 man; aged 20−42 years) developed systemic sarcoidosis following treatment with alemtuzumab for multiple sclerosis (MS) [not all outcomes stated].

Case 1: The woman, who had relapsing MS, received IV alemtuzumab 12 mg/day for 5 consecutive days, followed by 12 mg/day for 3 consecutive days 12 months later. Thirty five months after the initiation of alemtuzumab therapy, she developed therapy-associated autoimmune hypothyroidism. Three years and eight months following the first dose of alemtuzumab, a further relapse was noted. She again received alemtuzumab 12 mg/day for 3 consecutive days, resulting in inactive disease. Four years later (at the age of 42 years), she...

Reference

  1. Willis MD, et al. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal 24: 1779-1782, No. 13, Nov 2018. Available from: URL: http://doi.org/10.1177/1352458518790391 - UnitedKingdomCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations